June 27, 2019

Better Treatments Needed to Boost Brain Cancer Survival: Study

By Karl W Oestreich

HealthDay

Glioblastoma brain cancer remains one of deadliest tumors, and new research shows five-year survival rates remain low for patients with the disease. While there have been improvements in short- and medium-term survival rates for patients with the most common type of brain tumor in adults, only 6% of patients live for five years after diagnosis, according to the Mayo Clinic researchers.

Reach: HealthDay distributes its health news to media outlets several times each day and also posts its news on its website, which receives more than 379,000 unique visitors each month. HealthDay stories appears in 40 newspapers around the world and on television stations in 4 of the 10 markets and is also used by hospitals, clinics, private practices, non-profit organizations and government agencies.

Health Day Logo

Additional coverage:US News & World Report

Context: Despite improvements in median and short-term survival rates for patients with glioblastoma, the most common brain tumor in adults, the percentage of patients achieving five-year survival remains low, according to new Mayo Clinic research.

A study to be published next month in Mayo Clinic Proceedings finds that little has changed in terms of five-year survival — only 5.5% of patients live for five years after diagnosis — and calls for more aggressive treatments to be considered for all glioblastoma patients. You can read more on Mayo Clinic News Network.

Contacts: Tia Ford, Joe Dangor

Tags: brain tumors, Dr. Daniel Trifiletti, Dr. Paul D. Brown, Glioblastoma, Health Day, Mayo Clinic in Florida, Mayo Clinic Proceedings, Uncategorized

Contact Us · Privacy Policy